[6-K] MediWound Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

MediWound Ltd. filed a Form 6-K reporting submission of its quarterly materials for the period ended June 30, 2025. The report attaches a press release and the companys financial statements for the quarter and six months ended June 30, 2025, formatted in XBRL. The filing lists the specific XBRL sub-exhibits and states these materials are incorporated by reference into multiple S-8 and F-3 registration statements. The document does not include numerical results or management commentary within the main text of the 6-K itself.

Insights

Financial Analyst

TL;DR: Routine regulatory filing attaching XBRL-formatted interim financials and a press release; no standalone financial metrics in the 6-K text.

The filing is procedural: it delivers the companys Q2 and six-month 2025 financial statements in XBRL and incorporates those exhibits by reference into existing registration statements. For investors and analysts, the material value lies in the attached exhibits (press release and financial statements) rather than the 6-K cover letter. Because this form does not present headline revenue, profit or cash figures in-line, one must open the referenced exhibits to assess performance and trends.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure that documents submission of interim financials and preserves incorporation into prior registration statements.

The report demonstrates standard disclosure practice for a foreign private issuer: submission of interim results in XBRL and explicit incorporation by reference into prior S-8 and F-3 filings. This supports regulatory transparency and record continuity for securities issued under those registrations. The filing itself raises no governance concerns; substantive review requires the referenced exhibits.

0001593984Q22025false--12-312025-06-30

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549
______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-36349

 MediWound Ltd.
(Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐
 

CONTENTS

Results of Operations and Financial Condition— Quarter and Six Months Ended June 30, 2025

On August 14, 2025, MediWound Ltd. (“MediWound” or the “Company”) issued a press release entitled “MediWound Reports Second Quarter 2025 Financial Results and Provides Company Updates,” in which MediWound reported its results of operations. A copy of that press release is attached to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1.

Attached hereto, as Exhibit 99.2 to this Form 6-K, is MediWound's financial statements, as of, and for the quarter and six months ended on, June 30, 2025.

Attached hereto as Exhibit 101 are the financial statements of MediWound as of, and for the quarter and six months ended on, June 30, 2025, formatted in XBRL (eXtensible Business Reporting Language), consisting of the sub-exhibits listed in the exhibit table below.

2

Exhibits

Exhibit
Number		Exhibit Description
99.1		Press release reporting MediWound’s financial results
99.2		Financial statements, as of, and for the quarter and six months ended on, June 30, 2025
EX-101.INS		XBRL Taxonomy Instance Document
EX-101.SCH		XBRL Taxonomy Extension Schema Document
EX-101.CAL		XBRL Taxonomy Calculation Linkbase Document
EX-101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB		XBRL Taxonomy Label Linkbase Document
EX-101.PRE		XBRL Taxonomy Presentation Linkbase Document

Incorporation by Reference

The contents of this Report of Foreign Private Issuer on Form 6-K (including the information contained in Exhibits 99.1 and 99.2, but excluding quotes of senior management of the Company), are hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 5, 2021, August 9, 2022 , August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023, August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively).

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 Date: August 14, 2025           MEDIWOUND LTD.   By:  /s/ Hani Luxenburg Name:  Hani Luxenburg Title:    Chief Financial Officer

4